ReviewNPJ precision oncology2019
Immunotherapeutic advances in gastrointestinal malignancies.
Review in NPJ precision oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The association of survival with adjuvant chemotherapy in patients with ypTNM stage I gastric cancer after neoadjuvant chemotherapy.World journal of surgical oncology · 2026Article
- Global analysis of T-cell groups reveals immunological features and common antigen targets of digestive tract tumors.Journal of cancer research and clinical oncology · 2024Article
- LncRNA-MUF: A Novel Oncogenic Star with Potential as a Biological Marker and Therapeutic Target for Gastrointestinal Malignancies.Journal of Cancer · 2024Review
- A novel artificial intelligence network to assess the prognosis of gastrointestinal cancer to immunotherapy based on genetic mutation features.Frontiers in immunology · 2024Article
- Mesenchymal stem cell-derived exosomes for gastrointestinal cancer.World journal of gastrointestinal oncology · 2021Review
- A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer.NPJ precision oncology · 2021Article
- The Emerging Role of Tissue-Resident Memory CD8Frontiers in oncology · 2021Review
- Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters.Frontiers in immunology · 2021Review
- Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers.Innovation (Cambridge (Mass.)) · 2020Review
- Immune characterization of metastatic colorectal cancer patients post reovirus administration.BMC cancer · 2020Article
- Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies.Journal for immunotherapy of cancer · 2020Review
- Efficacy of mesenchymal stem cells in the treatment of gastrointestinal malignancies.World journal of gastrointestinal oncology · 2020Review
- Glycoconjugation: An approach to cancer therapeutics.World journal of clinical oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is an important global issue with increasing incidence and mortality, placing a substantial burden on the healthcare system. Colorectal cancer is the third most common cancer diagnosed among men and women in US. It is estimated that in 2018 there will be 319,160 new diagnosis and 160,820 deaths related to cancer of the digestive system including both genders in the United States alone. Considering limited success of chemotherapy, radiotherapy, and surgery in treatment of these cancer patients, new therapeutic avenues are under constant investigation. Therapy options have consistently moved away from typical cytotoxic chemotherapy where patients with a given type and stage of the disease were treated similarly, to an individualized approach where a tumor is defined by its specific tissue characteristics /epigenetic profile, protein expression and genetic mutations. This review takes a deeper look at the immune-biological aspects of cancers in the gastrointestinal tract (entire digestive tract extending from esophagus/stomach to rectum, including pancreatico-biliary apparatus) and discusses the different treatment modalities that are available or being developed to target the immune system for better disease outcome.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.